Hungary Pharmaceuticals & Healthcare Report Q4 2013 - New Report Available
BMI View: Hungary's deteriorating outlook for pharmaceutical companies has contributed to its continued placement on the Special 301 Priority Watch List in the Pharmaceutical Research and Manufacturers of America (PhRMA)'s 2013 Annual Report to the US Trade Representative (USTR). Since the implementation of the Hungarian Pharma-economic Law (XCVIII/2006) and the Szell Kalman Plan, pharmaceutical expenditure has been drastically cut in Hungary in an effort to balance the state's budget. Such draconian measures have reduced drug expenditure in Hungary to 2006...
View full press release